康哲药业宣布,其用于治疗特应性皮炎的芦可替尼磷酸酯乳膏新药申请,已正式获得中国国家药品监督管理局的受理。这一进展标志着该药物在中国上市审批流程中迈出关键一步。
康哲药业宣布,其用于治疗特应性皮炎的芦可替尼磷酸酯乳膏新药申请,已正式获得中国国家药品监督管理局的受理。这一进展标志着该药物在中国上市审批流程中迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.